Role of RGS proteins in Ras- and B-Raf--mediated transformation
Role of RGS proteins in Ras- and B-Raf--mediated transformation
批准号:
7245471
负责人:
CHANNING J. DER
金额:
$22.12万
依托单位国家:
美国
项目类别:
财政年份:
2007
资助国家:
美国
项目状态:
已结题
起止时间:
2007-04-11 至 2012-01-31
关键词:
BehaviorBindingBiologyCell LineCell ProliferationCell physiologyCellular biologyComplexDevelopmentEndosomesEpithelial CellsEvaluationFibroblastsFluorescenceGTP-Binding Protein RegulatorsGrowthHRAS geneHeterotrimeric GTP-Binding ProteinsLarge Intestine CarcinomaLightMAP Kinase GeneMEKsMalignant - descriptorMalignant Epithelial CellMediatingMitogen-Activated Protein KinasesMonomeric GTP-Binding ProteinsMutationNatureNormal CellOncogenesOncogenicOutputPathway interactionsPersonal SatisfactionPhosphotransferasesRGS ProteinsRNARaf Kinase InhibitorRas/RafRegulationRoleScaffolding ProteinSignal PathwaySignal TransductionSignaling MoleculeStructureTechniquesbasecancer cellcancer therapyinterestmelanomamutantneoplasticneoplastic cellnovel strategiesresearch clinical testingscaffoldsmall moleculetumorigenesistumorigenic
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The importance of the Ras small GTPases in normal cell physiology and the aberrant behavior of cancer cells is well-established. Ras functions' as a signaling node that regulates normal cell proliferation, differentiation and survival. The diverse cellular roles of Ras are mediated through Ras regulation of multiple, functionally distinct, downstream signaling networks, with the Raf-MEK-ERK mitogen-activated protein kinase (MARK) cascade the best understood. The mutational activation of Ras results in persistent, deregulated signaling that promotes the aberrant growth and behavior of malignant cancer cells. Consequently, there is considerable interest and effort in targeting Ras signaling for the development of novel approaches for cancer treatment. In particular, current evaluation is focused on clinical evaluation of small molecule kinase inhibitors of the Raf-MEK-ERK pathway. However, these efforts have been complicated by the fact that Ras can also utilize multiple Raf-independent effector pathways to promote oncogenesis. Furthermore, the Raf-MEK-ERK cascade is not a simple linear signaling pathway, but instead, represents the core of a complex signaling network that is regulated by an ever-expanding roster of functionally diverse signaling molecules. In particular, several scaffold proteins dictate the input signals that activate this kinase cascade and serve to diversify the spatial and temporal nature of the signaling output. Our recent preliminary observations determined that (a) the subfamily-D regulators of G protein signaling (RGS) proteins (RGS12 and RGS14) are putative effectors of Ras and that (b) RGS12 may function as a scaffold protein that regulates the Raf-MEK-ERK cascade. In light of the important role of the ERK MARK pathway in neoplastic cell biology, we hypothesize that RGS12 and RGS14 will be found to be important effectors of Ras-mediated oncogenesis and that RGS12 will be a critical regulator of Raf-MEK-ERK signaling and function. Four specific aims are proposed to critically evaluate the role of subfamily D RGS proteins in aberrant Ras and Raf signaling and oncogenesis to: (1) determine the roles of RGS12 and RGS14 as effectors of Ras-mediated oncogenes, (2) determine if RGS12 is critical for mutant B-Raf-mediated oncogenesis, (3) determine if RGS12 is an endosome-specific effector of Ras function, and (4) determine the structures of RGS12 (and/or RGS14) with Ras-MAPK binding partners.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Project 1: Targeting autophagy for the treatment of KRAS-mutant PDAC
-
批准号:10705570
-
项目类别:
-
资助金额:$41.52万
-
财政年份:2022
-
负责人:CHANNING J. DER
-
依托单位:
Project 1: Targeting autophagy for the treatment of KRAS-mutant PDAC
-
批准号:10334083
-
项目类别:
-
资助金额:$46.76万
-
财政年份:2022
-
负责人:CHANNING J. DER
-
依托单位:
Targeting undruggable RAS for cancer treatment
-
批准号:9605901
-
项目类别:
-
资助金额:$90.92万
-
财政年份:2018
-
负责人:CHANNING J. DER
-
依托单位:
Targeting undruggable RAS for cancer treatment
-
批准号:10465051
-
项目类别:
-
资助金额:$90.0万
-
财政年份:2018
-
负责人:CHANNING J. DER
-
依托单位:
The Role of RHOA in Diffuse Gastric Cancer
-
批准号:10416081
-
项目类别:
-
资助金额:$78.78万
-
财政年份:2018
-
负责人:CHANNING J. DER
-
依托单位:
Targeting undruggable RAS for cancer treatment
-
批准号:10229383
-
项目类别:
-
资助金额:$92.1万
-
财政年份:2018
-
负责人:CHANNING J. DER
-
依托单位:
Targeting undruggable RAS for cancer treatment
-
批准号:10669038
-
项目类别:
-
资助金额:$90.25万
-
财政年份:2018
-
负责人:CHANNING J. DER
-
依托单位:
Defining RAS isoform- and mutation-specific roles in oncogenesis
-
批准号:9302699
-
项目类别:
-
资助金额:$154.24万
-
财政年份:2016
-
负责人:CHANNING J. DER
-
依托单位:
Defining RAS isoform- and mutation-specific roles in oncogenesis
-
批准号:9074404
-
项目类别:
-
资助金额:$160.97万
-
财政年份:2016
-
负责人:CHANNING J. DER
-
依托单位:
Administrative and biostatistics core
-
批准号:9074405
-
项目类别:
-
资助金额:$15.13万
-
财政年份:2016
-
负责人:CHANNING J. DER
-
依托单位:
Defining RAS isoform- and mutation-specific roles in oncogenesis
-
批准号:9982047
-
项目类别:
-
资助金额:$160.94万
-
财政年份:2016
-
负责人:CHANNING J. DER
-
依托单位:
Admin-Core-001
-
批准号:10025409
-
项目类别:
-
资助金额:$6.48万
-
财政年份:2016
-
负责人:CHANNING J. DER
-
依托单位:
ERK inhibitor resistance and ERK isoform-dependent growth in pancreatic cancer
-
批准号:8643960
-
项目类别:
-
资助金额:$23.19万
-
财政年份:2014
-
负责人:CHANNING J. DER
-
依托单位:
Mechanisms of PAK1 activation, signaling and tumor resistance
-
批准号:8639302
-
项目类别:
-
资助金额:$37.07万
-
财政年份:2014
-
负责人:CHANNING J. DER
-
依托单位:
Mechanisms of PAK1 activation, signaling and tumor resistance
-
批准号:8800547
-
项目类别:
-
资助金额:$36.19万
-
财政年份:2014
-
负责人:CHANNING J. DER
-
依托单位:
ERK inhibitor resistance and ERK isoform-dependent growth in pancreatic cancer
-
批准号:8787721
-
项目类别:
-
资助金额:$17.48万
-
财政年份:2014
-
负责人:CHANNING J. DER
-
依托单位:
Mechanisms of PAK1 activation, signaling and tumor resistance
-
批准号:8998934
-
项目类别:
-
资助金额:$42.43万
-
财政年份:2014
-
负责人:CHANNING J. DER
-
依托单位:
Genetic dissection and inhibitor targeting of Rac signaling in pancreatic cancer.
-
批准号:8178826
-
项目类别:
-
资助金额:$19.31万
-
财政年份:2011
-
负责人:CHANNING J. DER
-
依托单位:
Genetic dissection and inhibitor targeting of Rac signaling in pancreatic cancer.
-
批准号:8298169
-
项目类别:
-
资助金额:$16.1万
-
财政年份:2011
-
负责人:CHANNING J. DER
-
依托单位:
Validation of Inhibitors of RhoGTPases for Cancer Treatment
-
批准号:7882866
-
项目类别:
-
资助金额:$25.91万
-
财政年份:2009
-
负责人:CHANNING J. DER
-
依托单位:
国内基金
海外基金
登录
查看更多内容
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
-
批准号:32170319
-
项目类别:面上项目
-
资助金额:58.00万元
-
批准年份:2021
-
负责人:董春海
-
依托单位:
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
-
批准号:--
-
项目类别:--
-
资助金额:58万元
-
批准年份:2021
-
负责人:董春海
-
依托单位:
ID1 (Inhibitor of DNA binding 1) 在口蹄疫病毒感染中作用机制的研究
-
批准号:31672538
-
项目类别:面上项目
-
资助金额:62.0万元
-
批准年份:2016
-
负责人:孙跃峰
-
依托单位:
番茄EIN3-binding F-box蛋白2超表达诱导单性结实和果实成熟异常的机制研究
-
批准号:31372080
-
项目类别:面上项目
-
资助金额:80.0万元
-
批准年份:2013
-
负责人:杨迎伍
-
依托单位:
P53 binding protein 1 调控乳腺癌进展转移及化疗敏感性的机制研究
-
批准号:81172529
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2011
-
负责人:杨其峰
-
依托单位:
DBP(Vitamin D Binding Protein)在多发性硬化中的作用和相关机制的蛋白质组学研究
-
批准号:81070952
-
项目类别:面上项目
-
资助金额:35.0万元
-
批准年份:2010
-
负责人:刘师莲
-
依托单位:
研究EB1(End-Binding protein 1)的癌基因特性及作用机制
-
批准号:30672361
-
项目类别:面上项目
-
资助金额:24.0万元
-
批准年份:2006
-
负责人:徐宁志
-
依托单位: